Neurovalens Secures £6m Funding to Expand Neurostimulation Solutions
Deal News | Aug 19, 2025 | UK Tech Funding
Neurovalens, a Belfast-based health tech company, has successfully raised £6 million in a new funding round, roughly a year after its previous funding. This brings its total raised funds to about £20 million across equity and debt offerings. The company is known for developing wearable neurostimulation devices that provide non-invasive treatment for mental health conditions such as insomnia, anxiety, and PTSD. The recent funding was led by the Investment Fund for Northern Ireland with additional contributions from Whiterock, IQ Capital, Innovation Ulster, and the Angel Co-Fund. The infusion of capital will be channelled toward scaling current device sales and extending the product lineup through further FDA approvals. Neurovalens underscores its innovative approach to addressing significant health challenges through safe neurostimulation techniques. The Investment Fund for Northern Ireland, managed by Clarendon Fund Managers, is a £70 million vehicle supported by the British Business Bank.
Sectors
- Healthcare Technology
- Venture Capital
Geography
- United Kingdom – Neurovalens is based in Belfast, UK, and many of the investors, including the Investment Fund for Northern Ireland, are UK-based.
- Northern Ireland – The Investment Fund for Northern Ireland led the latest funding round.
Industry
- Healthcare Technology – Neurovalens operates within the healthcare technology space, developing wearable medical devices that offer treatments for mental health conditions via neurostimulation.
- Venture Capital – The article discusses a funding round involving venture capital firms, highlighting an important angle of investment in technology.
Financials
- £6 million – The amount raised in the latest funding round by Neurovalens.
- £20 million – The total funds raised by Neurovalens to date, including equity and debt rounds.
- £2.1 million – The amount Neurovalens raised in April of the previous year.
- £70 million – The size of the Investment Fund for Northern Ireland.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Neurovalens | Target Company | Company | A Belfast-based health tech firm specializing in non-invasive neurostimulation technology. |
| Investment Fund for Northern Ireland | Lead Investor | Company | A £70 million fund backed by the British Business Bank and managed by Clarendon Fund Managers. |
| Whiterock | Investor | Company | An investor contributing to the latest funding round for Neurovalens. |
| IQ Capital | Investor | Company | A venture capital firm investing in the recent Neurovalens funding round. |
| Innovation Ulster | Investor | Company | Contributed to the funding round as an investor in Neurovalens. |
| Angel Co-Fund | Investor | Company | One of the contributing investors in the Neurovalens funding round. |
| British Business Bank | Sponsor | Government | Supports the Investment Fund for Northern Ireland as a financial backer. |
| Clarendon Fund Managers | Fund Manager | Company | Manages the Investment Fund for Northern Ireland. |
| Dr. Jason McKeown | CEO | Person | Chief Executive Officer of Neurovalens, commenting on the new investment. |
| Brian Cummings | Investment Director | Person | Investment director at Clarendon Fund Managers, expressing ongoing support for Neurovalens. |